Vera Praxis raises angel round from Boyu Capital for AI4S data
What's the deal? Chinese startup Vera Praxis (万衍) has raised an angel round from Boyu CapitalDealroom has a profile for this one. Try Dealroom → (博裕创投), the company announced in November 2026. It is founded and led by chief executive officer Weng Heming, who also sits on the board of listed firm Snibe (新产业生物) and serves as chief executive officer of its venture arm.
What's the endgame? Vera Praxis works in AI4S — artificial intelligence for scientific research. It supplies frontier model developers with specialist training data, evaluations, and interactive environments, turning the judgment and feedback of frontline experts into resources that models can learn from.
The product: Its in-house system, Praxis OS, is an enterprise-grade agent operation and collaboration platform for professional work. It connects domain experts, frontier models, and real work environments, letting companies probe the limits of model capabilities while converting industry know-how into measurable, improvable intelligence.
By the numbers: The company says its overall business has reached annual recurring revenue of several hundred million yuan. Its core data team includes 11 PhDs with experience at Tencent, Alibaba, ByteDance, and Meituan, and more than 60 top-tier conference and journal papers between them.
Why now? The round lands as Chinese AI4S and AI drug-discovery funding heats up, with recent deals including BioGeometry's A round of over $100 million. Vera Praxis takes a different position: rather than developing drugs, it sells the training data, evaluations, and workflows that underpin the models themselves.
The company says its Feyospace-v1.1 ranked among the global top five on the official CyberGym model leaderboard, alongside models from OpenAI, Google, Alibaba, and Zhipu. "High-quality specialist training data, interactive environments, and effective feedback from industry experts are an important foundation for models to solve complex professional problems," Boyu Capital said.
The signal: As frontier models mature, value is shifting toward the specialist inputs that make them useful in high-stakes fields such as life sciences. Vera Praxis is a bet that converting expert experience into model-ready data — not building drugs directly — is where industrial AI4S capability pays off.
Read more: sohu.com
Image credit: U.S. Army Combat Capabilities Development Command
